AI-Designed Oncology Molecules Move Toward the Next Discovery Stage

A new partnership is putting AI-powered molecular design at the center of an oncology discovery program. Isomorphic Labs announced on November 19, 2026, that it will work with MSD to discover small-molecule drug candidates against an oncology target the companies describe as strategically important.
The collaboration brings together Isomorphic Labs’ IsoDDE drug-design engine, MSD’s proprietary research data, and discovery expertise from a pharmaceutical company. The work begins at the early discovery stage, so no existing candidate is entering preclinical or clinical development through this announcement.
AI Design Meets Proprietary Drug Research Data
Isomorphic Labs will apply IsoDDE, a computational system composed of foundational AI models used for drug design. The engine will receive selected high-quality proprietary datasets from MSD, along with program-specific inputs that support the collaboration’s oncology focus.
Those data will be incorporated into IsoDDE for the program, giving the computational system access to research material selected by MSD for this work. Isomorphic Labs will combine that material with its own modeling and computing capabilities, then perform in silico predictions and deliver molecular designs.
The stated aim is direct: design and create better candidates faster by connecting MSD’s internal data and discovery expertise with Isomorphic Labs’ computational systems. That approach places an AI design engine alongside pharmaceutical research material, linking molecular prediction with the knowledge gathered through discovery work.
Sarah Skerratt, chief research officer at Isomorphic Labs, said the companies will apply IsoDDE’s generative and predictive capabilities to a challenging program intended to benefit patient populations with unmet needs.
From Computational Predictions to Laboratory Development
The agreement divides responsibilities between computational design and downstream drug development. Isomorphic Labs will handle the computational predictions and molecular designs, creating the proposed candidates through IsoDDE and the collaboration’s program-specific inputs.
MSD will take responsibility for preclinical and clinical development, manufacturing, and commercialization of any products derived from the collaboration. That division gives each company a defined role, but it also makes coordination essential: a molecular design must still move through MSD’s preclinical and clinical work before it could become a manufactured and commercialized product.
George Addona, senior vice president and head of Discovery, Preclinical Development and Translational Medicine at MSD Research Laboratories, emphasized the operational connection between computational and laboratory work.
“The key to successfully leveraging AI/ML for molecular invention lies in close coordination of wet-lab and dry-lab functions,” he said.
That connection sits at the heart of the program. Computational predictions can propose molecular designs, while laboratory research and later development determine how those designs progress. The partnership assigns the design system to Isomorphic Labs and the development path to MSD, creating a workflow that joins both functions from the beginning.
Why the Early Discovery Stage Matters
This announcement focuses on discovery rather than a drug candidate already moving into testing. The partners will work against an oncology target they describe as strategically important, but the collaboration has not announced an existing candidate entering preclinical or clinical development.
That distinction matters because AI-generated molecular designs represent an early step in the path toward a product. Isomorphic Labs will deliver computational predictions and molecular designs, while MSD will assess the resulting work through its preclinical and clinical development responsibilities.
MSD is the trade name used by Merck & Co., Inc., outside the United States and Canada. Its role in this collaboration includes supplying selected proprietary datasets and applying its discovery expertise, followed by responsibility for preclinical and clinical development, manufacturing, and commercialization of products derived from the work.
For Isomorphic Labs, the program puts IsoDDE’s generative and predictive capabilities to work on a challenging oncology effort. For MSD, it creates a defined connection between internal research data and an AI system designed to generate molecular predictions.
The collaboration now moves into the work of turning computational designs into candidates that can face preclinical and clinical development. If the program produces promising molecular designs, MSD will lead those downstream steps, while Isomorphic Labs’ role centers on the computational foundation that begins the discovery process.
Based on
- Isomorphic Labs and MSD Partner on AI Oncology Drug Discovery — unite.ai
- How AI and Anticancer Peptides Could Reshape the Future of Cancer Treatment | Markets Insider — markets.businessinsider.com
- Isomorphic Labs raises $5B led by Greenoaks and Sequoia — axios.com
- Scientist.com Launches Pharma Observatory, an Agent-First Market Intelligence Platform for Biopharma R&D | AFP.com — afp.com




